CAR-T and engineered T cell therapies

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

83 papers

Showing 73-83 of total 83 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2017OpenAlex

Sattva S. Neelapu; Frederick L. Locke; Nancy L. Bartlett; Lazaros J. Lekakis; David B. Miklos; Caron A. Jacobson; Ira Braunschweig; Olalekan O. Oluwole; Tanya Siddiqi; Yi Lin; John M. Timmerman; Patrick J. Stiff; Jonathan W. Friedberg; Ian W. Flinn; André Goy; Brian T. Hill; Mitchell R. Smith; Abhinav Deol; Umar Farooq; Peter A. McSweeney; Javier Muñoz; Irit Avivi; Januario E. Castro; Jason R. Westin; Julio C. Chávez; Armin Ghobadi; Krishna V. Komanduri; Ronald Levy; Eric D. Jacobsen; Thomas E. Witzig; Patrick M. Reagan; Adrian Bot; John M. Rossi; Lynn Navale; Yizhou Jiang; Jeff Aycock; Meg Elias; David Chang; Jeff Wiezorek; William Y. Go

Dec 10, 2017New England Journal of Medicine

2017OpenAlexSupporting evidence512 citations

Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma

Martin Lauss; Marco Donia; Katja Harbst; Rikke Andersen; Shamik Mitra; Frida Rosengren; Maryem Salim; Johan Vallon‐Christersson; Therese Törngren; Anders Kvist; Markus Ringnér; Inge Marie Svane; Göran Jönsson

Nov 17, 2017Nature Communications

2015OpenAlexSupporting evidence4,842 citations

Neoantigens in cancer immunotherapy

Ton N. Schumacher; Robert D. Schreiber

Apr 2, 2015Science

2015OpenAlexSupporting evidence4,842 citations

Neoantigens in cancer immunotherapy

Ton N. Schumacher; Robert D. Schreiber

Apr 2, 2015Science

2015OpenAlexSupporting evidence2,364 citations

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

Sandip Pravin Patel; Razelle Kurzrock

Feb 19, 2015Molecular Cancer Therapeutics

2015OpenAlexSupporting evidence2,364 citations

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

Sandip Pravin Patel; Razelle Kurzrock

Feb 19, 2015Molecular Cancer Therapeutics

2013OpenAlexSupporting evidence3,536 citations

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

Stephan A. Grupp; Michael Kalos; David M. Barrett; Richard Aplenc; David L. Porter; Susan R. Rheingold; David T. Teachey; Anne Chew; Bernd Hauck; J. Fraser Wright; Michael C. Milone; Bruce L. Levine; Carl H. June

Mar 25, 2013New England Journal of Medicine

2011CrossrefSupporting evidence73 citations

White Paper on Adoptive Cell Therapy for Cancer with Tumor-Infiltrating Lymphocytes: A Report of the CTEP Subcommittee on Adoptive Cell Therapy

Jeffrey Weber; Michael Atkins; Patrick Hwu; Laszlo Radvanyi; Mario Sznol; Cassian Yee

Apr 1, 2011Clinical Cancer Research

2010OpenAlexSupporting evidence96 citations

MM–GBSA binding free energy decomposition and T cell receptor engineering

Vincent Zoete; Melita Irving; Olivier Michielin

Feb 11, 2010Journal of Molecular Recognition

2002OpenAlexSupporting evidence1,216 citations

Adoptive T cell therapy using antigen-specific CD8 + T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells

Cassian Yee; John A. Thompson; D. Byrd; Stanley R. Riddell; Patrick C. Roche; Esteban Celis; Philip D. Greenberg

Nov 11, 2002Proceedings of the National Academy of Sciences

1992OpenAlexSupporting evidence184 citations

Immunoregulatory functions for murine intraepithelial lymphocytes: gamma/delta T cell receptor-positive (TCR+) T cells abrogate oral tolerance, while alpha/beta TCR+ T cells provide B cell help.

Kohtaro Fujihashi; Takashi Taguchi; Wilhelm K. Aicher; Jerry R. McGhee; Jeffrey A. Bluestone; John H. Eldridge; Hiroshi Kiyono

Mar 1, 1992The Journal of Experimental Medicine

Evidence

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma

Neoantigens in cancer immunotherapy

Neoantigens in cancer immunotherapy

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

White Paper on Adoptive Cell Therapy for Cancer with Tumor-Infiltrating Lymphocytes: A Report of the CTEP Subcommittee on Adoptive Cell Therapy

MM–GBSA binding free energy decomposition and T cell receptor engineering

Adoptive T cell therapy using antigen-specific CD8 + T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells

Immunoregulatory functions for murine intraepithelial lymphocytes: gamma/delta T cell receptor-positive (TCR+) T cells abrogate oral tolerance, while alpha/beta TCR+ T cells provide B cell help.